Latest News and Press Releases

SHANGHAI, China and CUPERTINO, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...

SHANGHAI, China and CUPERTINO, Calif., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...

SHANGHAI, China and CUPERTINO, Calif., Aug. 08, 2018 (GLOBE NEWSWIRE) -- China Food and Drug Administration (CFDA) Accepts the Company’s Investigational New Drug (IND) Applications for anti-CD19...

SHANGHAI, China and CUPERTINO, Calif., June 22, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...

SHANGHAI, China and CUPERTINO, Calif., June 21, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...

China Food and Drug Administration Accepts the Company’s Investigational New Drug (IND) Applications for anti-CD19 CAR-T Therapy Targeting NHL and ALLPositive 48-Week Phase I Clinical Data of...

SHANGHAI, China and CUPERTINO, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...

SHANGHAI, China and CUPERTINO, Calif., March 23, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...

中国上海市与加州库伯提诺市, March 21, 2018 (GLOBE NEWSWIRE) -- 西比曼生物科技集团（NASDAQ:CBMG，简称“CBMG”或“公司”） 是一家从事癌症免疫疗法和退行性疾病干细胞疗法开发的临床阶段生物制药公司。于中国杭州举办的“纳斯达克创新医药企业中国峰会暨杭州CBD论坛（CHIPS2018）”上，西比曼生物科技集团（CBMG）公司干细胞事业部（Stem...

SHANGHAI, China and CUPERTINO, Calif., March 16, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in...